Management of Regenics AS

Henrik Lund, Chief Executive Officer

Henrik Lund joined Regenics in 2014. Lund is an MD PhD from University of Oslo and received his post-doctoral training at UC San Francisco in lipidology. In 2005 – 2010 Lund served as VP of
AstraZeneca's Marketing Company clinical development group. He has also served as CEO and Chairman of the Board of several Norwegian biotech/life science companies and is at present Chairman Board of Directors Oslo Cancer Cluster, NCE. Lund works as CEO for Regenics from his own consultancy company.

 

Christian Clemm, Chief Medical Officer

Christian Clemm joined Regenics in 2014. He is an MD from University of Oslo and has an MBA from Norwegian School of Management BI. He has more than 20 years of experience from the pharmaceutical industry, including positions as VP Healthcare Affairs in AstraZeneca Nordic Baltic and Regional Clinical Research Director in AstraZeneca Latin America. Previously, he has served as member of the board in several Norwegian life science companies, Oslo Cancer Cluster and Norwegian Bioindustry Association.

Karin Giljam, Product Developer

Karin is a PhD coming to Regenics AS from University of Oslo. Biochemistry, Department of Molecular Medicine. Immunology. Previously she had a Post Doc position at , Norwegian University of Science and Technology, Department of Cancer research and molecular medicine. Karin will coordinate the Horizon 2020 3D AquaHeal EU commision project during 2020-2021

Bernat Rocarols, R&D Engineer

Bernat Rocarols, heads up the role of R&D Engineer. Bernat is a Biomedical Engineer graduated from Universitat Pompeu Fabra, Barcelona and currently pursuing a Master on Innovation and Entrepreneurship at the University of Oslo. Bernat has previously been Clinical Research Associate for Novartis through their CRO partner InVentiv Health, Barcelona in the area of cardiology and dermatology. He is also president of Innovation Forum Oslo and coach at INSJ UiO.

Bernat Rocarols: br@regenics.no
 
 

Mitchell Jones, Patent Attorney (US), JD PhD

Dr. Mitchell Jones is in charge of Regenics AS patents, trademarks and IP strategy since 2010. Dr. Jones is a founding shareholder of Casimir Jones S.C., Madison, Wisconsin, US. Dr. Jones recieved his, Juris Doctor, 1997 from Vanderbilt University and a Ph.D., Endocrinology-Reproductive Physiology, in 1994 from the University of Tennessee. Dr. Jones has extensive experience in obtaining, litigating and licensing patents with special emphasis in patents in life science disciplines, and has obtained hundreds of patents worldwide for clients. Dr. Jones has experience in representing US and international companies, from start-ups to Fortune 500 companies, as well as leading United States universities. Dr. Jones work for Regenics AS as a consultant.

 

Markus Heldrup, Researcher

Markus Heldrup joined Regenics in 2014. He has a BSc degree from University of Oslo in Biochemistry. Heldrup. Markus is now a researcher and device developer within wound healing and device section of Regenics. Markus also oversees production, analysis and quality control at the Company's Research and production site at Regenics Labs, Storo, Oslo, Norway

 

Hege O'Wiidt, Research Technician

Hege O'Wiidt, support Regenics AS with temporary research technician work. Hege O'Wiidt is a certified animal nurse from NBU (Norwegian University of Life Sciences) and works at Dept. of Comparative Medicine, Oslo University Hospital.

 

 

 

Contacts management:

Henrik Lund, CEO

mobile +47 90971219
henrik.lund@regenics.no

--

Christian Clemm, CMO

mobile +47 90795116
cc@regenics.no

--

Karin Gilljam, Product Developer

mobile +47 91809887

kg@regenics.no

--

Bernat Rocarols, Business Developer

mobile +34 691077398

br@regenics.no

--

Mitchell Jones, Patent Attourney

mobile +1 608 6621277
jmjones@casimirjones.com

--

Markus Heldrup, CPO

mobile +47 40462843
mh@regenics.no

--

Hege O'Wiidt, Research Technician

mobile +47 99713681
how@regenics.no

--

Anne-Karine Haflan, CE marking, QA Assurance

Regenics AS have developed clinical proof of efficacy and safety  in human 2 degree burn wounds for our products Collex® and Vernex®.

The procudts are beeing developed as class III devices. WoundClear® is developed as a BLA/EU CP biotech drug.